Tin tức & Cập nhật
Xem bài viết Dược
Xem
Chỉ hiển thị Multimedia

Two DOACs show similar bleeding risks in head-to-head VTE trial
23 Dec 2025
bởiAudrey Abella
In a post hoc analysis of the RENOVE trial, the direct oral anticoagulants (DOACs) rivaroxaban and apixaban demonstrate comparable risks of clinically relevant bleeding (CRB) and recurrent venous thromboembolism (VTE). These were observed across the crude, adjusted, and IPTW* analyses.
Two DOACs show similar bleeding risks in head-to-head VTE trial
23 Dec 2025
Insulin glargine improves glycaemic control in T2D patients in India
22 Dec 2025
bởiAudrey Abella
Findings from the prospective PRIMARY-INDIA study presented at ATTD-Asia 2025 show clinically meaningful improvements in glycaemic control with insulin glargine in individuals with type 2 diabetes (T2D) in primary care settings, with a consistent safety profile.







